Abstract: Provided is a method for construction of bone substitutes efficient in the repair of large bone defects. The method for constructing such medical products includes three-dimensional printing of a bioresorbable scaffold and its activation by gene constructions. Produced medicinal products may serve as an efficient alternative to bone autografts.

Abstract: Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode a modified vascular endothelia growth factor (VEGF) and a fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure encoding modified vascular endothelial growth factors (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.

Abstract: Provided are gene-activated materials comprising a scaffold and at least one nucleic acid molecule which may be chemical bound together or in which the at least one nucleic acid is not bound but coated on a surface of the scaffold. Methods for regenerating bone using these gene-activated materials are also provided.

Abstract: Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode a modified vascular endothelia growth factor (VEGF) and a fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure encoding modified vascular endothelial growth factors (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.

Abstract: Provided is a biocomposite including cells, a genetic construction, and a scaffold and a method for repairing tissue and organs in mammalians with the biocomposite. The interaction of the components of the biocomposite provides a complex effect on reparative regeneration processes. Also provided is a method for administration of gene-cellular therapeutic constructions to a recipient which can be used in medicine and veterinary to provide reparative processes. After administering the biocomposite to a recipient, the scaffold structure releases the nucleic acids which enter into the cells of a recipient bed and cells of the transplanted product. The nucleic acids are expressed, which results in the increased concentration of a target product responsible for reparative processes.

Abstract: Provided is a method for construction of bone substitutes efficient in the repair of large bone defects. The method for constructing such medical products includes three-dimensional printing of a bioresorbable scaffold and its activation by gene constructions. Produced medicinal products may serve as an efficient alternative to bone autografts.

Abstract: Provided is a method for treating a peripheral nervous system damage or injury, or for regenerating peripheral nervous system tissue that involves administering to a subject in need thereof a vector that comprises polynucleotide sequences that encode vascular endothelia growth factor (VEGF) and fibroblast growth factor (FGF2) and further a polynucleotide that encodes resistance to kanamycin. A gene-therapeutic structure coding vascular endothelial growth factor (VEGF) and (FGF-2) is also provided. The gene-therapeutic structure can be administered directly to a damaged nerve and paraneural tissues both in intraoperative and post-operative period to stimulate peripheral nerve regeneration. The structure and method significantly advance existing methods for reconstructive treatment for damaged peripheral nerves.

Abstract: Provided is a pharmaceutical composition for growth induction in blood vessel tissue which contains purified plasmid DNA encoding a vascular endothelial growth factor (VEGF) and pharmaceutically acceptable excipients that include a cryoprotectant as a vehicle and/or a pH stabilizer for stabilizing the pH in the range of 7.0 to 9.0, in effective quantities. Also provided is a storage method of plasmid DNA which encodes a VEGF comprising mixing the purified plasmid DNA with a solution of at least one cryoprotectant having properties of a vehicle and/or a pH stabilizer in the pH range of 7.0-9.0. The solution is lyophilized and stored at +2 to +8° C. Supercoiled DNA pCMV-VEGF165 may be used which is produced by culturing Esherichia coli strain TOP10/pCMV-VEGF165. The pharmaceutical composition is administered to a human in quantities sufficient to provide a necessary therapeutic effect.

Abstract: Provided is a pharmaceutical composition for growth induction in blood vessel tissue which contains purified plasmid DNA encoding a vascular endothelial growth factor (VEGF) and pharmaceutically acceptable excipients that include a cryoprotectant as a vehicle and/or a pH stabilizer for stabilizing the pH in the range of 7.0 to 9.0, in effective quantities. Also provided is a storage method of plasmid DNA which encodes a VEGF comprising mixing the purified plasmid DNA with a solution of at least one cryoprotectant having properties of a vehicle and/or a pH stabilizer in the pH range of 7.0-9.0. The solution is lyophilized and stored at +2 to +8° C. Supercoiled DNA pCMV-VEGF165 may be used which is produced by culturing Esherichia coli strain TOP10/pCMV-VEGF165. The pharmaceutical composition is administered to a human in quantities sufficient to provide a necessary therapeutic effect.

Abstract: Provided is a biocomposite including cells, a genetic construction, and a scaffold and a method for repairing tissue and organs in mammalians with the biocomposite. The interaction of the components of the biocomposite provides a complex effect on reparative regeneration processes. Also provided is a method for administration of gene-cellular therapeutic constructions to a recipient which can be used in medicine and veterinary to provide reparative processes. After administering the biocomposite to a recipient, the scaffold structure releases the nucleic acids which enter into the cells of a recipient bed and cells of the transplanted product. The nucleic acids are expressed, which results in the increased concentration of a target product responsible for reparative processes.